Poltreg S.A.

Manufacture of pharmaceutical preparations

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2016-09-15
Share capital
591,645.60 PLN
Activity description

Poltreg is a company that specializes in Treg autoimmune therapy, focusing on developing cell therapies for autoimmune diseases. It has a pipeline that includes PTG007, a potential treatment for Type-1 Diabetes and Multiple Sclerosis, and is working on launching in-patient trials for CAR-Tregs in Multiple Sclerosis and Amyotrophic Lateral Sclerosis. The company also boasts world-class manufacturing capabilities and aims to bring Treg therapies to routine use as disease-modifying therapeutics.

Registered address
ul. Botaniczna 20, 80-298 Gdańsk, Poland
Phone
Social media
Electronic delivery address
AE:PL-66699-30611-EJVEW-31

Financials

Revenue history (in k)

Filing timeliness

1 of 6 financial statements was filed late (for 2023, 1 day late). All were audited by a statutory auditor.

  • 202523/06/2026
  • 202403/06/2025
  • 202316/07/2024
  • 202228/06/2023
  • 202111/07/2022
  • 202007/06/2021
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Stock quotes

PLN 18.55
-0.45 (-2.37%)
18.6018.7018.8018.9018.5510:0012:0014:0016:00
Open
PLN 18.95
High
PLN 18.95
Low
PLN 18.55
Volume
201
Avg. vol.
4.47K
Market cap
PLN 109.75M
P/E ratio
–
EPS
-PLN 4.13
Shares outstanding
5.92M
52-week
PLN 18.00 – 21.70
Dividend yield
–
Dividend
–
Ex dividend date
–
Exchange
GPW Main Market

Quarterly results

PeriodRevenueEBITNet profit
Q2 2026USD 64.83kUSD -1.50mUSD -1.53m
Q1 2026USD 67.53kUSD -1.77mUSD -1.83m
Q4 2025USD 25.11kUSD -1.50mUSD -1.50m
Q3 2025USD 50.23kUSD -1.52mUSD -1.52m

Results for Q3 2026:Nov 18, 2026

Statistics

How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.

Sector · Manufacturing8,632 / 24,548
Top 35%
City · Gdańsk1,086 / 7,502
Top 14%
Voivodeship · Pomorskie3,297 / 20,062
Top 16%
Country · Poland50,938 / 297,069
Top 17%

Results vs industry

Revenue
This companyUSD 2.70mMedianUSD 913.43kAverageUSD 25.82m
Net profit
This companyUSD -6.53mMedianUSD 14.22kAverageUSD 2.77m
Operating costs
This companyUSD 8.92mMedianUSD 846.99kAverageUSD 21.42m
Assets
This companyUSD 18.32mMedianUSD 897.46kAverageUSD 31.52m

News

Parexel to support PolTREG's European registration of the world's first Treg cell therapy for type 1 diabetes

Parexel to support PolTREG's European registration of the world's first Treg cell therapy for type 1 diabetes

GDAŃSK, Poland, July 31, 2026 – PolTREG S.A. (WSE: PTG), one of the global pioneers in Treg cell therapies, has entered into an agreement with Parexel International (IRL) Limited to support the preparation and submission of its Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for PTG-007.

Prof. Piotr Trzonkowski co-authored a prestigious publication in Frontiers in Science with a Nobel Prize winner

Prof. Piotr Trzonkowski co-authored a prestigious publication in Frontiers in Science with a Nobel Prize winner

The prestigious journal Frontiers in Science has published a review article, “Regulatory T cells: master orchestrators of immune tolerance and tissue homeostasis,” co-authored by Prof. Piotr Trzonkowski, President of the Management Board and Chief Scientific Officer of PolTREG SA. The article was prepared by a group of world leaders in regulatory T cell (Treg) research, including Dr. Frederick J. Ramsdell, winner of the 2025 Nobel Prize in Physiology or Medicine.

Dr. Michael Rosenblum, leading University of California (UCSF) immunologist and dermatologist appointed to Immuthera Scientific Advisory Board

Dr. Michael Rosenblum, leading University of California (UCSF) immunologist and dermatologist appointed to Immuthera Scientific Advisory Board

June 1, 2026 – Immuthera, the USA subsidiary of PolTREG S.A., an emerging leader in engineered T regulatory (CAR-Treg) cell therapies, today announced the appointment of renowned dermatologist and immunologist Michael Rosenblum, M.D., Ph.D., to its Scientific Advisory Board (SAB). Dr. Rosenblum will help guide the clinical advancement of Immuthera’s first-in-class CD6/CTLA4 CAR-Treg platform as it relates to the development of this therapy in severe dermatological and related autoimmune and…

PolTREG summarizes 2025 – the way to registration in Europe of the world's first TREG therapy for diabetes begins

PolTREG summarizes 2025 – the way to registration in Europe of the world's first TREG therapy for diabetes begins

PolTREG SA, a global leader in the development of therapies using T-regulatory T cells (TREGS), summarized 2025 and presented key milestones for 2026. The company has unique data on a global scale confirming the 12-year effectiveness of TREG therapy in the treatment of diabetes and is preparing to submit an application to the European Medicines Agency (EMA) for central marketing authorization for the therapy in the European Union.

PolTREG has completed the ABB process and will obtain funds to finance key projects with the highest therapeutic and commercial potential

PolTREG has completed the ABB process and will obtain funds to finance key projects with the highest therapeutic and commercial potential

This material is for informational purposes only and does not constitute an offer, nor is it made available, to promote, directly or indirectly, the purchase or acquisition of PolTREG SA securities, or to encourage, directly or indirectly, the purchase or acquisition of such securities. This report does not constitute advertising or promotional material prepared or published by PolTREG SA for the purpose of promoting the shares, their subscription, purchase, or offering, or to encourage…

PolTREG at Life Science Investor Day

PolTREG at Life Science Investor Day

On March 11 , representatives of PolTREG S.A. will take part in Life Science Investor Day , organized by Strefa Inwestorów , to discuss the outlook for the biotech sector and the company’s development plans.

Offer

  • Cell therapies
  • Regulatory T-cell therapies
  • Autoimmune disease therapies
  • Clinical trials

Websites

The site is available in: Polish and English.

  • poltreg.bioPoltreg – The future of medicine
    WordPress 7.1WPMLCloudflare

Public procurement

1 tender recorded as contractor, with a total value of $2,712,205.

SubjectAmount
145/WR/2024 - Provision of medical services involving the manufacture of a Treg lymphocyte preparation, an advanced therapy medicinal product for the treatment of patients with type 1 diabetes, for UCK
$2.7M

Job offers

The company lists 2 job openings on its own careers page: poltreg.bio/career.

Position
Biotechnology R&D specialist
Production biotechnologist

Authorized Representatives

Mariusz Jabłoński age 62 – Management Board Member
Marcin Krzysztof Kądziela age 31 – Attorney-in-fact (joint)
Piotr Trzonkowski age 52 – President of the Management Board

Manner of representation

If the management board consists of two or more members, each member of the management board is entitled to make declarations on behalf of the company independently. However, in property matters with a value exceeding PLN 50,000.00 (fifty thousand zlotys and zero groszy), joint action by two members of the management board is required to make declarations on behalf of the company.

Supervisory board

Wojciech Golak age 43 – Supervisory Board Member
Oktawian Zbigniew Jaworek age 51 – Supervisory Board Member
Marcin Jerzy Mierzwiński age 51 – Supervisory Board Member
Paweł Mańdok age 56 – Supervisory Board Member
Michał Wnorowski age 53 – Supervisory Board Member

Beneficial owners

Person

Bank accounts

Registered as a VAT taxpayer on 2015-07-03.

Debt

No entries in the National Debtors Register (KRZ).

MSiG notices

Publication dateEvent
Nov 26, 2021Bankruptcy notice
Jan 29, 2021Commercial Companies Code notice
Jan 20, 2021Liquidation opened
Feb 25, 2019Commercial Companies Code notice

Public aid

20 public aid cases recorded, with a total value of $16,077,740.

PurposeGross amount
Aid for research and development projects: industrial research
$336.4K
Aid for research and development projects: industrial research
$1.4M
Aid for research and development projects: experimental development
$174.6K

European Funds

7 projects recorded: 3 from FE lists ($4,536,644) and 4 Commission grants (FTS) ($3,875,338).

ProjectEU co-financing
Next generations of cell therapies in autoimmunology
$1.2M
Autoantigen-specific adoptive regulatory t cell therapy against type 1 diabetes (artide)
$450.3K
Autoantigen-specific adoptive regulatory t cell therapy against type 1 diabetes (artide)
$421.3K

Regulatory authorisations

AuthorityTypeStatus
BDO register entry Active

Competitors

Name
Ryvu Therapeutics S.A.
Aronpharma sp. z o.o.
Biotechna S.A.
Captor Therapeutics S.A.
SDS Optic S.A.
Fileclo sp. z o.o.
Bioceltix S.A.
Famicordtx S.A.
Human Biome S.A.
Multiqure S.A.

Change history

DateEvent
2026-04-16Share capital increase
2023-03-24Address change
2021-12-09Share capital increase
2020-12-23Share capital increase
2020-07-29Share capital increase

FAQ

Last updated: 2026-08-07